References

Reference articles

1. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 Jan 30 [Epub ahead of print].

2. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the Coronavirus Study Group. February 2020 [internet publication].

3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Mar 2 [Epub ahead of print].

4. World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. February 2020 [internet publication].

5. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. March 2020 [internet publication].

6. World Health Organization. Pneumonia of unknown cause – China. January 2020 [internet publication].

7. World Health Organization. Novel coronavirus – China. January 2020 [internet publication].

8. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 27 March 2020. March 2020 [internet publication].

9. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.

10. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 18 [Epub ahead of print].

11. Ludvigsson JF. Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr. 2020 Mar 23 [Epub ahead of print].

12. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020 Feb 5 [Epub ahead of print].

13. Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 2020 Feb 5 [Epub ahead of print].

14. Hong H, Wang Y, Chung HT, et al. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr Neonatol. 2020 Mar 10 [Epub ahead of print].

15. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020 Mar 16 [Epub ahead of print].

16. Centre for Evidence-Based Medicine; Brassey J, Heneghan C, Mahtani KR, et al. Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2). March 2020 [internet publication].

17. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.

18. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.

19. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Review. 2020 Mar 3 [Epub ahead of print].

20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.

21. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.

22. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Jan 29 [Epub ahead of print].

23. Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020 Jan 29;79:104212.

24. Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr;92(4):433-40.

25. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020 Mar 13 [Epub ahead of print].

26. Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020 Mar 26 [Epub ahead of print].

27. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-23.

28. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 6;69(9):245-6.

29. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17 [Epub ahead of print].

30. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. March 2020 [internet publication].

31. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. January 2020 [internet publication].

32. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Dec;9(1):386-9.

33. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Feb 12 [Epub ahead of print].

34. Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020 Feb 26 [Epub ahead of print].

35. Centre for Evidence-Based Medicine; Ferner RE, Murray PI, Aronson JK. Spreading SARS-CoV-2 through ocular fluids. March 2020 [internet publication].

36. Sun T, Guan J. Novel coronavirus and central nervous system. Eur J Neurol. 2020 Mar 26 [Epub ahead of print].

37. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7 [Epub ahead of print].

38. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 18 [Epub ahead of print].

39. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships: worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-52.

40. Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10).

41. Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020 Mar 13 [Epub ahead of print].

42. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 2020 Mar 23;368:m1165.

43. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Mar 25 [Epub ahead of print].

44. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.

45. Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. February 2020 [internet publication].

46. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. Emerg Infect Dis. 2020 May 17;26(5).

47. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 Mar 4 [Epub ahead of print].

48. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 Mar 6 [Epub ahead of print].

49. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2020 Mar 19 [Epub ahead of print].

50. Du Z, Xu X, Wu Y, et al. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020 Mar 19;26(6).

51. Frieden TR, Lee CT. Identifying and interrupting superspreading events-implications for control of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020 Mar 18;26(6).

52. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.

53. Hui DS. Super-spreading events of MERS-CoV infection. Lancet. 2016 Sep 3;388(10048):942-3.

54. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020 Mar 7;395(10226):809-15.

55. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020 Mar 17 [Epub ahead of print].

56. Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in China. Clin Infect Dis. 2020 Mar 12 [Epub ahead of print].

57. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020 Feb;9(1):51-60.

58. Zeng H, Xu C, Fan J, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA 2020 Mar 26 [Epub ahead of print].

59. Dong L, Tian J, He S, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA. 2020 Mar 26 [Epub ahead of print].

60. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020 Mar 26 [Epub ahead of print].

61. World Health Organization. Novel coronavirus (2019-nCoV) situation report - 6. January 2020 [internet publication].

62. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): symptoms. February 2020 [internet publication].

63. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 Mar 10 [Epub ahead of print].

64. Jiang X, Niu Y, Li X, et al. Is a 14-day quarantine period optimal for effectively controlling coronavirus disease 2019 (COVID-19)? March 2020 [internet publication].

65. Yu P, Zhu J, Zhang Z, et al. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020 Feb 18 [Epub ahead of print].

66. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020 Jan;25(4).

67. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 4 [Epub ahead of print].

68. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17. pii: S0006-291X(20)30339-9 [Epub ahead of print].

69. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742.

70. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Mar 12 [Epub ahead of print].

71. Hanff TC, Harhay MO, Brown TS, et al. Is there an association between COVID-19 mortality and the renin-angiotensin system: a call for epidemiologic investigations. Clin Infect Dis. 2020 Mar 26 [Epub ahead of print].

72. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 Feb 19 [Epub ahead of print].

73. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 Mar 23 [Epub ahead of print].

74. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11 [Epub ahead of print].

75. World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. March 2020 [internet publication].

76. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people who are at higher risk for severe illness. March 2020 [internet publication].

77. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12 [Epub ahead of print].

78. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020 Mar 20 [Epub ahead of print].

79. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25 [Epub ahead of print].

80. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020 Mar 16 [Epub ahead of print].

81. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020 Mar 20;18:20.

82. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2020 [internet publication].

83. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): prevention and treatment. February 2020 [internet publication].

84. Feng S, Shen C, Xia N, et al. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med. 2020 Mar 20 [Epub ahead of print].

85. World Health Organization. Advice on the use of masks in the community, during home care, and in health care settings in the context of COVID-19. March 2020 [internet publication].

86. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? March 2020 [internet publication].

87. Desai AN, Mehrotra P. Medical masks. JAMA. 2020 Mar 4 [Epub ahead of print].

88. Quilty BJ, Clifford S, CMMID nCoV working group2, et al. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). Eurosurveillance. 2020 Feb;25(5).

89. Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020 Feb 18 [Epub ahead of print].

90. Centers for Disease Control and Prevention. Initial investigation of transmission of COVID-19 among crew members during quarantine of a cruise ship: Yokohama, Japan, February 2020. March 2020 [internet publication].

91. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.

92. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Feb 26 [Epub ahead of print].

93. Centre for Evidence-Based Medicine; Mahtani KR, Heneghan C, Aronson JK. What is the evidence for social distancing during global pandemics? March 2020 [internet publication].

94. Lewnard JA, Lo LC. Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis. 2020 Mar 23 [Epub ahead of print].

95. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis. 2020 Mar 23 [Epub ahead of print].

96. Public Health England. Guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19. March 2020 [internet publication].

97. National Institutes of Health. NIH officials discuss novel coronavirus that recently emerged in China. January 2020 [internet publication].

98. Connelly D, Robinson J; The Pharmaceutical Journal. The race to stop COVID-19. March 2020 [internet publication].

99. Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020 Mar 3;:1-4.

100. ClinicalTrials.gov. Safety and immunogenicity study of 2019-nCov vaccine (mRNA-1273) to treat novel coronavirus. March 2020 [internet publication].

101. Chinese Clinical Trial Registry. A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector). March 2020 [internet publication].

102. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.

103. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ. 2020 Mar 25;368:m1182.

104. World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. March 2020 [internet publication].

105. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. March 2020 [internet publication].

106. European Centre for Disease Prevention and Control. Infection prevention and control for COVID-19 in healthcare settings. March 2020 [internet publication].

107. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020 Mar;104(3):246-51.

108. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28 [Epub ahead of print].

109. Sun P, Qie S, Liu Z, et al. Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection. J Med Virol. 2020 Feb 28 [Epub ahead of print].

110. Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020 Mar 12 [Epub ahead of print].

111. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606.

112. Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020 Mar 20 [Epub ahead of print].

113. Touzard-Romo F, Tapé C, Lonks JR. Co-infection with SARS-CoV-2 and human metapneumovirus. R I Med J (2013). 2020 Mar 19;103(2):75-6.

114. Wang XF, Yuan J, Zheng YJ, et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen [in Chinese]. Zhonghua Er Ke Za Zhi. 2020 Feb 17;58(0):E008.

115. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Mar 18 [Epub ahead of print].

116. Cai J, Xu J, Lin D, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020 Feb 28 [Epub ahead of print].

117. Liu W, Zhang Q, Chen J, et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med. 2020 Mar 12 [Epub ahead of print].

118. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. 2020 Mar 19 [Epub ahead of print].

119. Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China [in Chinese]. Zhonghua Er Ke Za Zhi. 2020 Feb 11;58(0):E005.

120. Wang J, Wang D, Chen GC, et al. SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate [in Chinese]. Zhongguo Dang Dai Er Ke Za Zhi. 2020 Mar;22(3):211-4.

121. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 Mar 5 [Epub ahead of print].

122. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12 [Epub ahead of print].

123. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. March 2020 [internet publication].

124. Ruan ZR, Gong P, Han W, et al. A case of 2019 novel coronavirus infected pneumonia with twice negative 2019-nCoV nucleic acid testing within 8 days. Chin Med J (Engl). 2020 Mar 5 [Epub ahead of print].

125. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020 Mar 11;26(6).

126. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Feb 27 [Epub ahead of print].

127. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect. 2020 Mar 11 [Epub ahead of print].

128. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020 Feb 6;200274.

129. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb 6;7(1):4.

130. Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020 Mar 14;:1-7.

131. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Feb 24 [Epub ahead of print].

132. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Mar 12 [Epub ahead of print].

133. Feng K, Yun YX, Wang XF, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection [in Chinese]. Zhonghua Er Ke Za Zhi. 2020 Feb 16;58(0):E007.

134. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Feb 26 [Epub ahead of print].

135. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.

136. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13:101623.

137. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Mar 24 [Epub ahead of print].

138. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19 [Epub ahead of print].

139. Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin Gastroenterol Hepatol. 2020 Mar 20 [Epub ahead of print].

140. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020 Mar 26 [Epub ahead of print].

141. ENT UK. Loss of sense of smell as marker of COVID-19 infection. March 2020 [internet publication].

142. American Academy of Otolaryngology - Head and Neck Surgery. Coronavirus disease 2019: resources. March 2020 [internet publication].

143. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020 Mar 26 [Epub ahead of print].

144. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for Dengue. J Am Acad Dermatol. 2020 Mar 22 [Epub ahead of print].

145. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020 Mar 13 [Epub ahead of print].

146. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Feb 19 [Epub ahead of print].

147. US Food and Drug Administration. Emergency use authorization: coronavirus disease 2019 (COVID-19) EUA information. March 2020 [internet publication].

148. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic. March 2020 [internet publication].

149. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Jan 24 [Epub ahead of print].

150. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Jan 30 [Epub ahead of print].

151. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. March 2020 [internet publication].

152. World Health Organization. Global surveillance for human infection with coronavirus disease (COVID-19). March 2020 [internet publication].

153. Centers for Disease Control and Prevention. Criteria to guide evaluation and laboratory testing for COVID-19. March 2020 [internet publication].

154. Infectious Diseases Society of America. COVID-19 prioritization of diagnostic testing. March 2020 [internet publication].

155. World Health Organization. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. March 2020 [internet publication].

156. World Health Organization. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. February 2020 [internet publication].

157. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.

158. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020 Mar 23 [Epub ahead of print].

159. Truog RD, Mitchell C, Daley GQ. The toughest triage: allocating ventilators in a pandemic. N Engl J Med. 2020 Mar 23 [Epub ahead of print].

160. White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. JAMA. 2020 Mar 27 [Epub ahead of print].

161. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020. March 2020 [internet publication].

162. National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. March 2020 [internet publication].

163. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). March 2020 [internet publication].

164. Centre for Evidence-Based Medicine; Park S, Brassey J, Heneghan C, et al. Managing fever in adults with possible or confirmed COVID-19 in primary care. March 2020 [internet publication].

165. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020 Mar 17;368:m1086.

166. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. March 2020 [internet publication].

167. NHS. Stay at home advice. March 2020 [internet publication].

168. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. March 2020 [internet publication].

169. Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med. 2020 Mar 20 [Epub ahead of print].

170. Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ. 2020 Mar 24;368:m1201.

171. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). March 2020 [internet publication].

172. Pan C, Chen L, Lu C, et al. Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study. Am J Respir Crit Care Med. 2020 Mar 23 [Epub ahead of print].

173. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 Mar 20 [Epub ahead of print].

174. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 Feb 15;395(10223):473-5.

175. Zhou YH, Qin YY, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J (Engl). 2020 Mar 5 [Epub ahead of print].

176. Dashraath P, Jing Lin Jeslyn W, Mei Xian Karen L, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020 Mar 23 [Epub ahead of print].

177. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Mar 3 [Epub ahead of print].

178. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 Mar 20 [Epub ahead of print].

179. Centers for Disease Control and Prevention. Interim considerations for infection prevention and control of coronavirus disease 2019 (COVID-19) in inpatient obstetric healthcare settings. February 2020 [internet publication].

180. Extance A. Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? BMJ. 2020 Mar 25;368:m1174.

181. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020 Mar 24 [Epub ahead of print].

182. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. March 2020 [internet publication].

183. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. March 2020 [internet publication]

184. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020 Mar 11 [Epub ahead of print].

185. Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. 2020 Mar 23;:1-9.

186. European Medicines Agency. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic. March 2020 [internet publication].

187. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Hobbs R. Inhaled steroids in asthma during the COVID-19 outbreak. March 2020 [internet publication].

188. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of radiotherapy. March 2020 [internet publication].

189. Naicker S, Yang CW, Hwang SJ, et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020 Mar 7 [Epub ahead of print].

190. National Institute for Health and Care Excellence. COVID-19 rapid guideline: dialysis service delivery. March 2020 [internet publication].

191. Centers for Disease Control and Prevention. Interim additional guidance for infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in outpatient hemodialysis facilities. March 2020 [internet publication].

192. Kliger AS, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol. 2020 Mar 20 [Epub ahead of print].

193. European Renal Association – European Dialysis and Transplant Association. COVID-19 news and information. 2020 [internet publication].

194. Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020 Mar 11 [Epub ahead of print].

195. British Society of Gastroenterology. BSG expanded consensus advice for the management of IBD during the COVID-19 pandemic. March 2020 [internet publication].

196. Danese S, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 Mar 25 [Epub ahead of print].

197. Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020 Mar 25 [Epub ahead of print].

198. McCreary EK, Pogue JM. COVID-19 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020 Mar 23 [internet publication].

199. Kalil AC. Treating COVID-19: off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA Mar 24 [Epub ahead of print].

200. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 18 March 2020. March 2020 [internet publication].

201. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-71.

202. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10 [Epub ahead of print].

203. Chinese Clinical Trial Registry. A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

204. Chinese Clinical Trial Registry. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

205. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019.

206. ClinicalTrials.gov. Post-exposure prophylaxis for SARS-coronavirus-2. March 2020 [internet publication].

207. ClinicalTrials.gov. Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting (COPCOV). March 2020 [internet publication].

208. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949.

209. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-8.

210. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Mar 20 [Epub ahead of print].

211. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36.

212. ClinicalTrials.gov. Mild/moderate 2019-nCoV remdesivir RCT. February 2020 [internet publication].

213. ClinicalTrials.gov. Severe 2019-nCoV remdesivir RCT. February 2020 [internet publication].

214. ClinicalTrials.gov. Adaptive COVID-19 treatment trial. March 2020 [internet publication].

215. ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). March 2020 [internet publication].

216. ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. March 2020 [internet publication].

217. Gilead Sciences. Remdesivir. March 2020 [internet publication].

218. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3 [Epub ahead of print].

219. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 Mar 18 [Epub ahead of print].

220. Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Feb 27 [Epub ahead of print].

221. ClinicalTrials.gov. Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19. March 2020 [internet publication].

222. ClinicalTrials.gov. Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19. March 2020 [internet publication].

223. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Mar 27 [Epub ahead of print].

224. US Food and Drug Administration. Investigational COVID-19 convalescent plasma: emergency INDs. March 2020 [internet publication].

225. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. February 2020 [internet publication].

226. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020 Mar 25;21(7).

227. ClinicalTrials.gov. Tocilizumab in COVID-19 pneumonia (TOCIVID-19). March 2020 [internet publication].

228. ClinicalTrials.gov. Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019. March 2020 [internet publication].

229. ClinicalTrials.gov. Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID-19 (TACOS). March 2020 [internet publication].

230. ClinicalTrials.gov. Tocilizumab for SARS-CoV2 severe pneumonitis. March 2020 [internet publication].

231. Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020 Mar 24 [Epub ahead of print].

232. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4 [Epub ahead of print].

233. ClinicalTrials.gov. Losartan for patients with COVID-19 requiring hospitalization. March 2020 [internet publication].

234. ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. March 2020 [internet publication].

235. Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020 Mar 13:105944.

236. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Mar 4 [Epub ahead of print].

237. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11 [Epub ahead of print].

238. ClinicalTrials.gov. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. March 2020 [internet publication].

239. BioSpace. Roivant announces development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19. March 2020 [internet publication].

240. CytoDyn Inc. Leronlimab used in seven patients with severe COVID-19 demonstrated promise with two intubated patients in ICU, removed from ICU and extubated with reduced pulmonary inflammation. March 2020 [internet publication].

241. Chinese Clinical Trial Registry. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP). February 2020 [internet publication].

242. Chinese Clinical Trial Registry. Clinical study for safety and efficacy of favipiravir in the treatment of novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

243. Chinese Clinical Trial Registry. Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

244. Chinese Clinical Trial Registry. Randomized, open-label, controlled trial for evaluating of the efficacy and safety of baloxavir marboxil, favipiravir, and lopinavir-ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients. February 2020 [internet publication].

245. Zeng YM, Xu XL, He XQ, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia. Chin Med J (Engl). 2020 Mar 5 [Epub ahead of print].

246. Li H, Wang YM, Xu JY, et al. Potential antiviral therapeutics for 2019 novel coronavirus [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-2.

247. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020 Mar 11 [Epub ahead of print].

248. ClinicalTrials.gov. Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-nCoV (DACO-nCoV). March 2020 [internet publication].

249. Synairgen. COVID-19. March 2020 [internet publication].

250. Royal Australian College of General Practitioners. Healthcare workers trial TB vaccine for coronavirus protection. March 2020 [internet publication].

251. Chinese Clinical Trial Registry. A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

252. Chinese Clinical Trial Registry. A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

253. Chinese Clinical Trial Registry. A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19). February 2020 [internet publication].

254. Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020 Mar 13:1-26.

255. World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020 [internet publication].

256. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. March 2020 [internet publication].

257. Rajgor DD, Lee MH, Archuleta S. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Mar 27 [Epub ahead of print].

258. Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020 Jan;25(3).

259. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 Mar 23 [Epub ahead of print].

260. Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020 Feb 18;368:m641.

261. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19 [Epub ahead of print].

262. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020 Mar 26 [Epub ahead of print].

263. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3 [Epub ahead of print].

264. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091.

265. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chinese Med J. 2020 Mar 20 [internet publication].

266. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24 [Epub ahead of print].

267. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020 Feb 28 [Epub ahead of print].

268. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 Mar 16 [Epub ahead of print].

269. Chen D, Xu W, Lei Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis. 2020 Mar 5 [Epub ahead of print].

270. Xing Y, Mo P, Xiao Y, et al. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill. 2020 Mar;25(10).

271. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020 Mar 11 [Epub ahead of print].

272. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13 [Epub ahead of print].

273. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 Mar 14 [Epub ahead of print].

274. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020 Mar 20 [Epub ahead of print].

275. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Mar 27 [Epub ahead of print].

276. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25 [Epub ahead of print].

277. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25 [Epub ahead of print].

278. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 15;48(0):E011.

279. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 Mar 21 [Epub ahead of print].

280. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27 [Epub ahead of print].

281. Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020 Mar 16 [Epub ahead of print].

282. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27 [Epub ahead of print].

283. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 Mar 18 [Epub ahead of print].

284. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16 [Epub ahead of print].

285. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar 27 [Epub ahead of print].

286. Liu D, Li L, Wu X, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. AJR Am J Roentgenol. 2020 Mar 18:1-6.

287. Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. 2020 Mar 20;26(7).

288. Centers for Disease Control and Prevention. Interim guidance for public health professionals managing people with COVID-19 in home care and isolation who have pets or other animals. March 2020 [internet publication].

289. IDEXX Laboratories. Leading veterinary diagnostic company sees no COVID-19 cases in pets. March 2020 [internet publication].

Use of this content is subject to our disclaimer